China Resources Sanjiu to reduce share capital after restricted share repurchase

China Resources Sanjiu Medical & Pharmaceutical announced on September 1, 2025, that its fifth extraordinary general meeting approved the repurchase and cancellation of 36,505 restricted shares from its 2021 Restricted Share Incentive Plan. This decision follows the termination of employment or failure to meet performance targets by six original incentive recipients. The cancelled shares represent approximately 0.002% of the company's pre-repurchase total share capital.

As a result of this action, the company's total share capital will decrease from 1,664,254,363 shares to 1,664,217,858 shares, leading to a corresponding reduction in registered capital. Creditors have 45 days from the announcement date to declare their claims and request debt settlement or guarantees, as per relevant laws.

The proposal to repurchase and cancel these restricted shares was approved by 99.9662% of the voting shareholders at the extraordinary general meeting, with 47,157,991 shares from small and medium investors voting in favor, representing 99.2175% of their total votes.